1. Generics Bulletin
  2. >>Business
  3. >>Strategy

The Ten-Year Plan: How Sandoz Sees GLP-1s Shaping Up

CEO Richard Saynor Also Talks ADCs, Oligonucleotides And Value Added Medicines

 
• By Dave Wallace

In the final instalment of his three-part interview with Generics Bulletin, Sandoz CEO Richard Saynor talks about opportunities on the horizon, including GLP-1s, ADCs and oligonucleotides – and explains why he has no interest in pursuing value added medicines.

Richard Saynor sets out the road to 2035 for GLP-1s (Shutterstock)

Having kicked off his three-part interview with Generics Bulletin by talking about Sandoz’s overall goals as a business before moving on to discuss the firm’s generics and biosimilars strategy in more detail, CEO Richard Saynor now turns to the fresh opportunities on the horizon for the company – particularly when it comes to the current industry favorite, GLP-1s.

Asked whether GLP-1s were the next biosimilars – in terms of a new frontier that off-patent industry leaders are becoming increasingly excited about conquering – Saynor said the comparison between...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

 
• By Dean Rudge

Teva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By Dean Rudge

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

Abiogen And mAbxience Join Forces In Italy

 
• By Dave Wallace

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.

Krka Looks To Kick On In India And China

 
• By Dean Rudge

Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.

More from Leadership

Samsung Bioepis Reevaluating Approach To Biosimilars

 
• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs

 
• By Dave Wallace

Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.